Kiora Pharmaceuticals, Inc.
KPRXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Kiora Pharmaceuticals, Inc. focuses on Biotechnology services and products. Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. The company carries a $10.1M market cap, placing it firmly in the micro-cap category. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Market Cap
$10.1M
Beta
-0.21
P/E (TTM)
—
P/E (Fwd)
-1.03
EPS (TTM)
$-2.43
EPS (Fwd)
$-2.23
ROE
-56.4%
ROA
-21.9%
Cash
$16.8M
Total Debt
$333,022
Free CF
-$6.4M
52W Change
-10.5%
Annual Financials
Cash vs Debt
Where KPRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KPRX finished 5.18% below its 150-day moving average ($2.51) and 1.24% below its 200-day moving average ($2.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KPRX overbought or oversold?
At the October 20, 2026 close, KPRX's RSI(14) was 21.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $16.8M in cash and $333K in debt, KPRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$6.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -56.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
KPRX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, KPRX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing KPRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.